 |
19 Diseases |  |
1 Trial |
|
1 Trial |  |
33 News |  |
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Aug 15, 2024
P1, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=40 --> 24
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Preclinical, Journal: Efficient ex vivo expansion of conserved element vaccine-specific CD8+ T-cells from SHIV-infected, ART-suppressed nonhuman primates. (Pubmed Central) - May 23, 2023
NHP CE-XTCs expanded up to 10-fold following co-culture with the combination of primary dendritic cells (DCs), PHA blasts pulsed with CE peptides, irradiated GM-K562 feeder cells, and autologous T cells from CE-vaccinated NHP...However, consistent with prior studies with human HXTC and these cells' predominant CD8 effector phenotype, we did not observe significant differences in CE-XTC persistence or SHIV acquisition in two CE-XTC-infused NHP compared to two control NHP. These data support the safety and feasibility of our approach and underscore the need for continued development of CE-XTC and similar cell-based strategies to redirect and increase the potency of cellular virus-specific adaptive immune responses.
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Mar 2, 2022
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
These data support the safety and feasibility of our approach and underscore the need for continued development of CE-XTC and similar cell-based strategies to redirect and increase the potency of cellular virus-specific adaptive immune responses. Trial primary completion date: Aug 2021 --> Aug 2023
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Nov 24, 2020
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Aug 2021 --> Aug 2023 Trial primary completion date: Aug 2020 --> Aug 2021
- | imatinib / Generic mfg.
Trial completion, Enrollment change, Trial completion date: Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Oct 28, 2020
P1, N=3, Completed, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Aug 2020 --> Aug 2021 Active, not recruiting --> Completed | N=30 --> 3 | Trial completion date: Jan 2022 --> Sep 2020
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change, Trial completion date, Tumor cell, Metastases: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination (clinicaltrials.gov) - Sep 17, 2020
P1, N=27, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=30 --> 3 | Trial completion date: Jan 2022 --> Sep 2020 Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Jul 2021 --> Apr 2020
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Trial completion date, Metastases: Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (clinicaltrials.gov) - Sep 16, 2020
P1, N=33, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | N=40 --> 27 | Trial completion date: Jul 2021 --> Apr 2020 Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2020
- | imatinib / Generic mfg.
Trial completion date: Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Mar 6, 2020
P1, N=30, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial completion date: Dec 2026 --> Jan 2020 Trial completion date: Jan 2020 --> Jan 2022
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion date, Trial termination, Trial primary completion date, Surgery, Tumor cell, Metastases: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum (clinicaltrials.gov) - Mar 3, 2020
P1, N=19, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jan 2020 --> Jan 2022 Trial completion date: Jun 2014 --> Feb 2020 | Completed --> Terminated | Trial primary completion date: Jun 2014 --> Feb 2020; Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none developed a response, the protocol would stop accrual.
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion date, Trial termination, Tumor cell: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - Mar 3, 2020
P1, N=10, Terminated, Sponsor: National Cancer Institute (NCI)
Trial completion date: Jun 2014 --> Feb 2020 | Completed --> Terminated | Trial primary completion date: Jun 2014 --> Feb 2020; Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none developed a response, the protocol would stop accrual. Trial completion date: Mar 2015 --> Feb 2020 | Completed --> Terminated; Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population.
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Nov 20, 2019
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Mar 2015 --> Feb 2020 | Completed --> Terminated; Closed accrual due to unpromising results and the opening of study 14C0053 targeting the same population. Trial primary completion date: Aug 2019 --> Aug 2020
- | imatinib / Generic mfg.
Trial completion date: Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia (clinicaltrials.gov) - Feb 8, 2019
P1, N=30, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Aug 2019 --> Aug 2020 Trial completion date: Jan 2019 --> Jan 2020
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Oct 30, 2018
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial completion date: Jan 2019 --> Jan 2020 Trial primary completion date: Aug 2018 --> Aug 2019
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Mar 13, 2018
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Aug 2018 --> Aug 2019 Trial primary completion date: Dec 2017 --> Mar 2018
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Clinical, Journal: Vaccination with autologous myeloblasts admixed with GM-K562 cells in patients with advanced MDS or AML after allogeneic HSCT. (Pubmed Central) - Jan 4, 2018
GM-K562/leukemia cell vaccination induces biologic activity, even in patients transplanted with active MDS/AML. This study is registered at www.clinicaltrials.gov as #NCT 00809250.
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment closed, Metastases: Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (clinicaltrials.gov) - Nov 18, 2017
P1, N=33, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
This study is registered at www.clinicaltrials.gov as #NCT 00809250. Terminated --> Active, not recruiting
- | Leukine (sargramostim) / Partner Therap
Enrollment closed, Enrollment change, Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Jul 17, 2017
P2, N=36, Active, not recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Terminated --> Active, not recruiting Recruiting --> Active, not recruiting | N=56 --> 36 | Trial primary completion date: Dec 2017 --> Jul 2020
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change, Trial primary completion date: Vaccination With Lethally Irradiated Glioma Cells Mixed With GM-K562 Cells in Patients Undergoing Craniotomy For Recurrent Tumor (clinicaltrials.gov) - Jun 22, 2017
P1, N=11, Completed, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | N=56 --> 36 | Trial primary completion date: Dec 2017 --> Jul 2020 Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jun 2011 --> Aug 2009
- | allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Jun 2, 2017
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | N=25 --> 11 | Trial primary completion date: Jun 2011 --> Aug 2009 Trial primary completion date: May 2017 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - May 19, 2016
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: May 2017 --> Dec 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Nov 10, 2015
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Dec 2016 --> Dec 2017 Trial primary completion date: Dec 2015 --> Dec 2016
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Nov 1, 2015
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Trial primary completion date: Dec 2015 --> Dec 2016 Trial primary completion date: May 2015 --> May 2017
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change, Tumor cell: Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas (clinicaltrials.gov) - Mar 23, 2015
P1, N=10, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: May 2015 --> May 2017 Recruiting --> Completed | N=25 --> 10
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment closed, Trial primary completion date: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Feb 13, 2015
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | N=25 --> 10 Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015
- || Leukine (sargramostim) / Partner Therap
Trial primary completion date: Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI (clinicaltrials.gov) - Sep 29, 2014
P2, N=56, Recruiting, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Recruiting --> Active, not recruiting | Trial primary completion date: May 2014 --> May 2015 Trial primary completion date: Dec 2014 --> Dec 2015
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial primary completion date, Surgery, Tumor cell, Metastases: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum (clinicaltrials.gov) - Jun 26, 2014
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Dec 2015 Trial primary completion date: Feb 2018 --> Jun 2014
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment change, Surgery, Tumor cell, Metastases: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum (clinicaltrials.gov) - Jun 26, 2014
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Feb 2018 --> Jun 2014 N=25 --> 19
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial completion, Enrollment change, Trial primary completion date, Surgery, Tumor cell, Metastases: Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum (clinicaltrials.gov) - Jun 26, 2014
P1, N=19, Completed, Sponsor: National Cancer Institute (NCI)
N=25 --> 19 Recruiting --> Completed | N=25 --> 19 | Trial primary completion date: Feb 2018 --> Jun 2014
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment closed, Tumor cell, Metastases: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination (clinicaltrials.gov) - Feb 5, 2014
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Completed | N=25 --> 19 | Trial primary completion date: Feb 2018 --> Jun 2014 Recruiting --> Active, not recruiting
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Trial termination, Metastases: Vaccination With GM-K562 Cells in Patients With Advanced Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) After Allogeneic Hematopoetic Stem Cell Transplantation (clinicaltrials.gov) - Dec 17, 2012
P1, N=33, Terminated, Sponsor: Dana-Farber Cancer Institute
Recruiting --> Active, not recruiting Suspended --> Terminated
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment open: Vaccination for the Treatment of Previously Untreated or Relapsed Follicular Lymphoma (clinicaltrials.gov) - Sep 16, 2012
P1, N=40, Recruiting, Sponsor: Dana-Farber Cancer Institute
Suspended --> Terminated Active, not recruiting --> Recruiting
- allogeneic K562-GM tumor cell vaccine / National Cancer Institute
Enrollment change, Tumor cell, Metastases: Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination (clinicaltrials.gov) - Aug 6, 2012
P1, N=40, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Recruiting N=24 --> 40